Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.
REPORT DATE (DD-MM-YYYY)
SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) 10. SPONSOR/MONITOR'S ACRONYM(S)
U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012
SPONSOR/MONITOR'S REPORT NUMBER(S)
DISTRIBUTION / AVAILABILITY STATEMENTApproved for Public Release; Distribution Unlimited
SUPPLEMENTARY NOTES
ABSTRACTWe tested whether reactivation of the inactive X chromosome in the mouse mammary gland contributes to tumorigenesis in vivo and whether that reactivation of the inactive X can cooperate with the MYC oncogene in tumor progression. We found no evidence for a role of reactivation of the inactive X in tumor initiation or progression. We also examined whether the inactive X was reactivated in a number of different mouse breast cancers and found not evidence to support reactivation. Finally, these studies directly lead to an examination of whether the BRCA1 promotes breast cancer by affecting the function of Xist RNA during X-inactivation, and found that Xist RNA and X-inactivation are unaffected in BRCA1 mutant cells and cancers.
SUBJECT TERMSEpigenetics, breast cancer, X chromosome inactivation, loss of heterozygousity, Xist, Brca1